Dogwood Therapeutics, Inc. (DWTX) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.17
↓-87% vs avg
5yr avg: 1.33
30Y Low0.0·High2.9
ROE
↑
-49.2%
↓+33% vs avg
5yr avg: -72.9%
30Y Low-112%·High-36%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DWTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Dogwood Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $52M | $34M | $3M | $11M | $3M | $43M | $37M | — | — |
| Enterprise Value | $46M | $28M | $3M | $7M | $-4418448 | $29M | $7M | — | — |
| P/E Ratio → | -0.36 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.17 | 0.46 | 0.04 | 2.84 | 0.36 | 2.94 | 1.24 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DWTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
DWTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -49.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.2% | -49.2% | -36.3% | -95.1% | -112.2% | -71.8% | -82.8% | — | — |
| ROA | -37.1% | -37.1% | -25.1% | -84.5% | -101.4% | -67.6% | -65.1% | -1295.7% | -3205.6% |
| ROIC | -31.4% | -31.4% | -28.0% | -1040.2% | -2343.1% | -3675.0% | — | — | — |
| ROCE | -31.4% | -31.4% | -25.8% | -97.8% | -112.8% | -70.4% | -69.9% | — | — |
DWTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $7M exceeds total debt of $162604, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.24 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | 0.01 | -0.87 | -0.96 | -0.97 | -1.00 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -132.96 | — | — | — | -26.04 | -7.38 | -12.90 |
Net cash position: cash ($7M) exceeds total debt ($162604)
DWTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Dogwood Therapeutics, Inc.'s current ratio of 2.76x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 11.62x to 2.76x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.76 | 2.76 | 5.21 | 11.62 | 8.02 | 12.37 | 20.55 | 0.19 | 0.03 |
| Quick Ratio | 2.76 | 2.76 | 5.21 | 11.62 | 8.02 | 12.37 | 20.55 | 0.19 | 0.03 |
| Cash Ratio | 2.13 | 2.13 | 4.67 | 9.25 | 6.74 | 10.98 | 19.45 | 0.19 | 0.02 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
DWTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Dogwood Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 0.2% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.2% | — | — |
| Shares Outstanding | — | $8M | $1M | $751071 | $442804 | $333172 | $197079 | $193299 | $193299 |
Peer Comparison
Compare DWTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DWTXYou | $52M | -0.4 | — | — | — | — | -49.2% | -31.4% | — |
 PRGO | $1B | -1.0 | 7.1 | 9.8 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PCRX | $878M | 139.6 | 9.4 | 6.4 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 CRL | $9B | -63.6 | 12.9 | 17.2 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 IQV | $28B | 21.4 | 12.4 | 13.9 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 MEDP | $13B | 30.1 | 22.9 | 19.3 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 ICLR | $11B | 50.3 | 10.1 | 13.0 | 26.4% | 12.3% | 2.5% | 6.2% | 2.5 |
 PFE | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 ATHA | $17M | -0.2 | — | — | — | — | -290.8% | — | — |
 SRRK | $6B | -14.4 | — | — | — | — | -123.1% | -201.2% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
DWTX — Frequently Asked Questions
Quick answers to the most common questions about buying DWTX stock.
What is Dogwood Therapeutics, Inc.'s P/E ratio?
Dogwood Therapeutics, Inc.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
What is Dogwood Therapeutics, Inc.'s ROE?
Dogwood Therapeutics, Inc.'s return on equity (ROE) is -49.2%. The historical average is -74.6%.
Is DWTX stock overvalued?
Based on historical data, Dogwood Therapeutics, Inc. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.